Deutsche Bank Aktiengesellschaft Initiates Coverage on Medline (NASDAQ:MDLN)

Investment analysts at Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday, Marketbeat reports. The brokerage set a “hold” rating and a $40.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential downside of 1.28% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. Cowen started coverage on shares of Medline in a report on Monday. They issued a “buy” rating for the company. Sanford C. Bernstein assumed coverage on Medline in a research report on Monday. They issued an “outperform” rating and a $49.00 target price for the company. Truist Financial set a $52.00 price objective on shares of Medline and gave the company a “buy” rating in a research note on Monday. Redburn Partners set a $42.00 target price on Medline in a report on Monday. Finally, Robert W. Baird began coverage on Medline in a research report on Monday. They set an “outperform” rating and a $48.00 price objective for the company. Eighteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.25.

Medline Trading Down 1.8%

MDLN stock opened at $40.52 on Monday. Medline has a 12-month low of $34.89 and a 12-month high of $45.50.

Insider Buying and Selling at Medline

In related news, Director Charles N. Mills bought 2,579,310 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. This trade represents a -1,870.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the transaction, the insider owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This trade represents a 55.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.